Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
COSTS AND EXPENSES:    
Research and development $ 2,308,397 $ 2,124,060
General and administrative 1,321,415 1,329,467
Total costs and expenses 3,629,812 3,453,527
LOSS FROM OPERATIONS (3,629,812) (3,453,527)
OTHER INCOME (EXPENSE):    
Loss on revaluation of derivative warrants (4,000) (26,950)
Interest income, net 12,171 4,654
Total other income (expense), net 8,171 (22,296)
NET LOSS $ (3,621,641) $ (3,475,823)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.76) $ (2.07)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 4,773,500 1,680,818